Researchers at Stanford Medicine have developed a nasal spray vaccine that protected mice against an unprecedented range of respiratory threats — from SARS-CoV-2 and other coronaviruses to dangerous hospital-acquired bacteria like Staphylococcus aureus and Acinetobacter baumannii, and even house dust mite allergens linked to asthma. The findings, published February 19 in Science, represent the closest approach yet to a universal respiratory vaccine.

Unlike conventional vaccines that train the immune system to recognize specific pathogens, this one mimics the communication signals immune cells use during active infections. Led by postdoctoral scholar Haibo Zhang and senior author Bali Pulendran, the team combined toll-like receptor stimuli with a harmless protein to activate both innate and adaptive immunity. The result is a "double whammy" — sustained innate response slashes viral levels dramatically while adaptive immunity kicks in within 3 days instead of the usual two weeks.

With adequate funding, Pulendran estimates a universal respiratory vaccine could reach patients within five to seven years, pending Phase I safety trials in humans.